Authors: Xinda Yang, Chuansheng Xu, Youliang Zeng, Chunhui Wang, Yan Gao, Jie Ding, Sirui Chen, Yuheng Pan, Xin Zhang, Zongwan Mao, Shuo Shi
Published: 2025-05-28
Source: Full article
AbstractPyroptosis has attracted significant attention for its role in cancer chemotherapy and immunotherapy. However, few drugs have been reported to induce pyroptosis via the Caspase‐3/gasdermin E (GSDME) pathway. Herein, three novel PtIV prodrugs, MRP, DRP, and HRP are rationally designed by conjugating DNA methyltransferase (DNMT) inhibitor (RG108) and/or histone deacetylase (HDAC) inhibitor (PhB) to the PtIV center. These prodrugs can be easily reduced to cisplatin (CDDP) due to the high glutathione (GSH) levels in tumors, liberating the coordinated ligands. Released RG108 reactivates the GSDME gene and reduces pyroptosis in low GSDME‐expressing tumor cells. Meanwhile, PhB‐induced chromatin loosening enhances CDDP‐DNA binding, which not only increases Caspase‐3 expression, but also upregulates GSDME. HRP demonstrates superior ability to suppress tumor growth and metastasis while reducing systemic toxicity compared with CDDP. By reactivating GSDME and loosening chromatin, HRP effectively boosts tumor cell pyroptosis and exhibits the most pronounced anticancer performance. These findings highlight HRP’s potential as a therapeutic agent for triple‐negative breast cancer (TNBC) and offer innovative strategies for combining chemotherapy with immunotherapy. To the best of current knowledge, this is the first report of platinum complexes inducing pyroptosis via the Caspase‐3/GSDME pathway in low GSDME‐expressing tumor cells.